CARA THERAPEUTICS INC (CARA) Stock Price, Quote, News and Overview
NASDAQ:CARA - Nasdaq - US1407552082 - Common Stock - Currency: USD
CARA Quote, Performance and Key Statistics
5.32
-0.23 (-4.14%)
The current stock price of CARA is 5.32 USD. In the past month the price increased by 2.31%. In the past year, price decreased by -32.93%.
CARA Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 63.39 | 781.24B | ||
| JNJ | JOHNSON & JOHNSON | 15.36 | 372.06B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 17.51 | 271.23B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.85 | 217.14B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 16.51 | 212.37B | ||
| MRK | MERCK & CO. INC. | 10.26 | 197.21B | ||
| SNY | SANOFI-ADR | 11.7 | 129.16B | ||
| PFE | PFIZER INC | 7.2 | 126.93B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 42.18 | 97.83B | ||
| GSK | GSK PLC-SPON ADR | 8.45 | 74.84B | ||
| ZTS | ZOETIS INC | 25.49 | 67.31B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 32.28 | 47.74B |
Related stock screener links
About CARA
Company Profile
CARA Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors (KORs). The company is headquartered in Stamford, Connecticut and currently employs 10 full-time employees. The company went IPO on 2014-01-31. The firm is focused on treatment paradigm to improve the lives of patients suffering from chronic pruritus. The company is developing an oral formulation of difelikefalin, a selective, predominantly peripherally acting, non-scheduled Kappa opioid receptor agonist, for the treatment of chronic neuropathic pruritus associated with Notalgia Paresthetica (NP), a common, underdiagnosed neuropathy affecting the upper back. The company is conducting Phase II/III Clinical Program in NP. The program is comprised of two studies - KOURAGE 1 and KOURAGE 2, which are double-blind, placebo-controlled, eight-week studies with patients allowed to roll-over into open-label 52-week extensions. The company has developed an IV formulation of difelikefalin, for the treatment of moderate-to-severe pruritus associated with advanced chronic kidney disease in adults undergoing hemodialysis. The IV formulation is out-licensed worldwide.
Company Info
CARA THERAPEUTICS INC
400 Atlantic Street, Suite 500
Stamford CONNECTICUT 06902 US
CEO: Derek Chalmers
Employees: 55
Company Website: https://www.caratherapeutics.com/
Investor Relations: https://ir.caratherapeutics.com/
Phone: 12034063700
CARA THERAPEUTICS INC / CARA FAQ
What is the stock price of CARA THERAPEUTICS INC today?
The current stock price of CARA is 5.32 USD. The price decreased by -4.14% in the last trading session.
What is the ticker symbol for CARA THERAPEUTICS INC stock?
The exchange symbol of CARA THERAPEUTICS INC is CARA and it is listed on the Nasdaq exchange.
On which exchange is CARA stock listed?
CARA stock is listed on the Nasdaq exchange.
What is CARA THERAPEUTICS INC worth?
CARA THERAPEUTICS INC (CARA) has a market capitalization of 24.31M USD. This makes CARA a Nano Cap stock.
How many employees does CARA THERAPEUTICS INC have?
CARA THERAPEUTICS INC (CARA) currently has 55 employees.
What are the support and resistance levels for CARA THERAPEUTICS INC (CARA) stock?
CARA THERAPEUTICS INC (CARA) has a support level at 5.06 and a resistance level at 5.5. Check the full technical report for a detailed analysis of CARA support and resistance levels.
Is CARA THERAPEUTICS INC (CARA) expected to grow?
The Revenue of CARA THERAPEUTICS INC (CARA) is expected to decline by -25% in the next year. Check the estimates tab for more information on the CARA EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy CARA THERAPEUTICS INC (CARA) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of CARA, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of CARA, evaluating the profitability, health, valuation and growth aspects
- CARA THERAPEUTICS INC (CARA) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- CARA THERAPEUTICS INC (CARA) Sales and EPS estimates to see what analysts future expectations are.
- CARA THERAPEUTICS INC (CARA) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- CARA THERAPEUTICS INC (CARA) Insider and Institutional Ownership to learn about the owners and their transactions.
- CARA THERAPEUTICS INC (CARA) Stock Chart to make your own analysis
- CARA THERAPEUTICS INC (CARA) Latest news and press-releases to stay up to date.
Does CARA THERAPEUTICS INC (CARA) stock pay dividends?
CARA does not pay a dividend.
When does CARA THERAPEUTICS INC (CARA) report earnings?
CARA THERAPEUTICS INC (CARA) will report earnings on 2025-05-12, after the market close.
What is the Price/Earnings (PE) ratio of CARA THERAPEUTICS INC (CARA)?
CARA THERAPEUTICS INC (CARA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-15.55).
What is the Short Interest ratio of CARA THERAPEUTICS INC (CARA) stock?
The outstanding short interest for CARA THERAPEUTICS INC (CARA) is 1.67% of its float. Check the ownership tab for more information on the CARA short interest.
CARA Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to CARA. When comparing the yearly performance of all stocks, CARA is a bad performer in the overall market: 60.43% of all stocks are doing better.
CARA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to CARA. The financial health of CARA is average, but there are quite some concerns on its profitability.
CARA Financial Highlights
Over the last trailing twelve months CARA reported a non-GAAP Earnings per Share(EPS) of -15.55. The EPS decreased by -612.03% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -161.7% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
CARA Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 43% to CARA. The Buy consensus is the average rating of analysts ratings from 6 analysts.
For the next year, analysts expect an EPS growth of 40% and a revenue growth -25% for CARA